New MGA Analysis of the Adalimumab Biosimilars Market in the United States
Below is the press release from Biosimilars Council regarding the new report from MGA examining biosimilar competition for Humira (adalimumab) in the US market.
Washington, D.C. (February 21, 2023) – The Biosimilars Council released the following statement in response to the new Matrix Global Advisors report Near-Term Expectations for Adalimumab Biosimilars in the United States, authored by Alex Brill and Christy Robinson:
“This new report from Matrix Global Advisors illustrates the complexities of the burgeoning adalimumab biosimilar market. While biosimilars bring much needed competition and reduce overall costs, perverse rebate practices and other market factors will unnecessarily slow patient access and savings from FDA-approved biosimilars,” said Craig Burton, Executive Director of the Biosimilars Council. “Policymakers should ensure that patients have access to and benefit from lower-priced biosimilars.”
MEDIA CONTACT:
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.
